MedPath

SCREENING FOR THE IMPLANTATION OF A SUBCUTANEOUS IMPLANTABLE AUTOMATIC DEFIBRILLATOR

Not Applicable
Completed
Conditions
Sudden Cardiac Death
Implantable Defibrillator
Registration Number
NCT04101253
Lead Sponsor
Centre Hospitalier de PAU
Brief Summary

S-ICD (subcutaneous implantable cardioverter-defibrillator) screening failure occurs in about 10% of cases. Predictors of screening failure are not yet well determined. Moreover, slight variations in electrode positioning may change vector configuration and therefore improve screening success rates

Detailed Description

S-ICD (subcutaneous implantable cardioverter-defibrillator) has become the last years widespread in various pathological conditions and implantation rates are increasing each year worldwide. Previous to implantation it is mandatory to realize a screening in order to assess specific electrocardiographic vectors used to analyze cardiac rhythm. In routine practice, approximatively 10% of patients are recused for S-ICD device implantation due to failed screening 1-3. Causes are mainly abnormalities of R wave (low or high amplitude) and low R/T wave ratio. Determinants for screening failure have not yet been clearly studied. Moreover, it is a common finding in S-ICD implantation to find variations between pre-implant electrograms and electrograms recorded by the device. Variations of R wave amplitude and R/T ration are also observed with small variations of electrode positioning prior to implantation. It has been also shown that despite initial screening failure, S-ICD could be securely performed in some cases 4,5. Patients included in the study will undergo usual screening protocol. In case of failure a 2nd screening will be realize with slight electrode positioning variations compatible with S-ICD and lead placement. In case of success modality of implantation will be decided by physician.

In case of S-ICD implantation screening data will be compared to post implantation device electrograms. A 2 month follow-up will be performed with comparison of a new screening procedure with electrodes at the level of sub-cutaneous electrodes.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
480
Inclusion Criteria
  • The population will be composed of all patients referred for ICD method, aged over 18 years
Exclusion Criteria
  • Age < 18 years old
  • Patients who cannot freely give their consent, or patients who refuse to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
screening success ratesone day

Comparison of success rates between the standard screening procedure (without repositioning the electrodes) and the proposed new procedure (small variations in electrode positioning)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (16)

CHRU de BREST

🇫🇷

Brest, France

CHU de Caen

🇫🇷

Caen, France

CHRU de Lille

🇫🇷

Lille, France

Hopital Saint Philivert

🇫🇷

Lille, France

CHU de Limoges

🇫🇷

Limoges, France

Hopitl Cardiologique Louis Pradel

🇫🇷

Lyon, France

CHU de Nancy

🇫🇷

Nancy, France

CHU de Nantes

🇫🇷

Nantes, France

AP-HP Hôpital européen Georges-Pompidou

🇫🇷

Paris, France

APHP - Pitié Salpêtrière

🇫🇷

Paris, France

Scroll for more (6 remaining)
CHRU de BREST
🇫🇷Brest, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.